• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢透明细胞癌的细胞因子基因表达谱。

Cytokine gene expression signature in ovarian clear cell carcinoma.

机构信息

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.

出版信息

Int J Oncol. 2012 Sep;41(3):1094-100. doi: 10.3892/ijo.2012.1533. Epub 2012 Jun 26.

DOI:10.3892/ijo.2012.1533
PMID:22751940
Abstract

Cytokine expression in a tumor microenvironment can impact both host defense against the tumor and tumor cell survival. In this study, we sought to clarify whether the cytokine gene expression profile could have clinical associations with ovarian cancer. We analyzed the expression of 16 cytokine genes (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p35, IL-12p40, IL-15, IFN-γ, TNF-α, IL-6, HLA-DRA, HLA-DPA1 and CSF1) in 50 ovarian carcinomas. Hierarchical clustering analysis of these tumors was carried out using Cluster software and differentially expressed genes were examined between clear cell carcinoma (CCC) and other subtypes. Following this examination we evaluated the biological significance of IL-6 knockdown in CCC. Unsupervised hierarchical clustering analysis of cytokine gene expression revealed two distinct clusters. The relationship between the two clusters and clinical parameters showed statistically significant differences in CCC compared to other histologies. CCC showed a dominant Th-2 cytokine expression pattern driven largely by IL-6 expression. Inhibition of IL-6 in CCC cells suppressed Stat3 signaling and rendered cells sensitive to cytotoxic agents. The unique cytokine expression pattern found in CCC may be involved in the pathogenesis of this subtype. In particular, high IL-6 expression appears likely to be driven by the tumor cells, fueling an autocrine pathway involving IL-6 expression and Stat3 activation and may influence survival when exposed to cytotoxic chemotherapy. Modulation of IL-6 expression or its related signaling pathway may be a promising strategy of treatment for CCC.

摘要

肿瘤微环境中的细胞因子表达可以影响宿主对肿瘤的防御和肿瘤细胞的存活。在这项研究中,我们试图阐明细胞因子基因表达谱是否与卵巢癌具有临床相关性。我们分析了 50 例卵巢癌中 16 种细胞因子基因(IL-1α、IL-1β、IL-2、IL-4、IL-5、IL-8、IL-10、IL-12p35、IL-12p40、IL-15、IFN-γ、TNF-α、IL-6、HLA-DRA、HLA-DPA1 和 CSF1)的表达。使用 Cluster 软件对这些肿瘤进行层次聚类分析,并检查了透明细胞癌(CCC)和其他亚型之间差异表达的基因。在此检查之后,我们评估了 CCC 中 IL-6 敲低的生物学意义。细胞因子基因表达的无监督层次聚类分析显示出两个不同的簇。这两个簇与临床参数之间的关系在 CCC 与其他组织学相比显示出统计学上的显著差异。CCC 显示出主要由 IL-6 表达驱动的 Th2 细胞因子表达模式。在 CCC 细胞中抑制 IL-6 抑制了 Stat3 信号传导,并使细胞对细胞毒性药物敏感。在 CCC 中发现的独特细胞因子表达模式可能与该亚型的发病机制有关。特别是,高 IL-6 表达似乎很可能是由肿瘤细胞驱动的,推动涉及 IL-6 表达和 Stat3 激活的自分泌途径,并可能在暴露于细胞毒性化疗时影响生存。调节 IL-6 表达或其相关信号通路可能是治疗 CCC 的一种有前途的策略。

相似文献

1
Cytokine gene expression signature in ovarian clear cell carcinoma.卵巢透明细胞癌的细胞因子基因表达谱。
Int J Oncol. 2012 Sep;41(3):1094-100. doi: 10.3892/ijo.2012.1533. Epub 2012 Jun 26.
2
Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.Th1和Th2细胞因子mRNA的相对表达水平是卵巢癌患者独立的预后因素。
Oncol Rep. 2005 Jun;13(6):1153-8.
3
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.白细胞介素-6(IL-6)/白细胞介素-6受体(IL-6R)信号通路抑制在卵巢透明细胞癌中的抗肿瘤作用。
Mol Carcinog. 2016 May;55(5):832-41. doi: 10.1002/mc.22325. Epub 2015 Apr 9.
4
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.耐药性卵巢癌中信号转导及转录激活因子3通路的激活
Clin Cancer Res. 2006 Sep 1;12(17):5055-63. doi: 10.1158/1078-0432.CCR-06-0861.
5
The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival.人类结肠癌的细胞因子微环境。肿瘤坏死因子-α和白细胞介素-4的淋巴细胞表达预示着生存期延长。
Cancer. 1996 Sep 15;78(6):1168-78. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1168::AID-CNCR2>3.0.CO;2-6.
6
The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation.促炎细胞因子白细胞介素1β与缺氧通过缺氧诱导因子1的激活协同诱导卵巢癌细胞中肾上腺髓质素的表达。
Cancer Res. 2005 Jun 1;65(11):4690-7. doi: 10.1158/0008-5472.CAN-04-3877.
7
Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo.Stat6 活性相关的 Th2 细胞因子谱和人类结直肠癌细胞在体外和体内的生长优势。
Cell Signal. 2012 Mar;24(3):718-25. doi: 10.1016/j.cellsig.2011.11.005. Epub 2011 Nov 13.
8
Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression.骨桥蛋白在卵巢透明细胞癌中的过表达:与肝细胞核因子-1β表达密切相关。
Histopathology. 2008 May;52(6):682-8. doi: 10.1111/j.1365-2559.2008.03006.x. Epub 2008 Apr 2.
9
[Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].[白细胞介素-6诱导的卵巢癌细胞化疗耐药及其信号转导通路]
Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):691-8.
10
Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.西妥昔单抗对卵巢癌中 IL-6 诱导的信号通路的影响。
Clin Cancer Res. 2010 Dec 1;16(23):5759-69. doi: 10.1158/1078-0432.CCR-10-1095. Epub 2010 Aug 10.

引用本文的文献

1
Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.度伐鲁单抗对比医师选择的化疗方案用于复发性卵巢透明细胞腺癌(MOCCA/APGOT-OV2/GCGS-OV3):一项多中心、随机、2期试验
Clin Cancer Res. 2025 Sep 15;31(18):3907-3915. doi: 10.1158/1078-0432.CCR-25-0201.
2
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.从临床管理到个性化医学:卵巢透明细胞癌的新型治疗方法。
J Ovarian Res. 2024 Feb 12;17(1):39. doi: 10.1186/s13048-024-01359-7.
3
Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.
子宫内膜异位症相关卵巢癌:PI3K/AKT/mTOR 通路如何影响其发病机制。
Biomolecules. 2023 Aug 16;13(8):1253. doi: 10.3390/biom13081253.
4
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.针对肿瘤相关巨噬细胞进行卵巢癌的成功免疫治疗。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005968.
5
The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer.纳米材料在增强天然产物转化潜力及调节内质网应激以治疗卵巢癌中的作用。
Front Pharmacol. 2022 Oct 26;13:987088. doi: 10.3389/fphar.2022.987088. eCollection 2022.
6
Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma.聚焦于卵巢透明细胞癌相关高凝状态的治疗策略
Cancers (Basel). 2022 Apr 24;14(9):2125. doi: 10.3390/cancers14092125.
7
DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.卵巢透明细胞癌的 DNA 甲基化图谱。
Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):132-141. doi: 10.1158/1055-9965.EPI-21-0677. Epub 2021 Oct 25.
8
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.白细胞介素-6 作为卵巢透明细胞癌抗血管生成治疗的增强剂。
Sci Rep. 2021 Apr 8;11(1):7689. doi: 10.1038/s41598-021-86913-9.
9
Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer.炎症细胞因子在心血管疾病和癌症发病机制中的作用
SAGE Open Med. 2020 Oct 20;8:2050312120965752. doi: 10.1177/2050312120965752. eCollection 2020.
10
Precision medicine for ovarian clear cell carcinoma based on gene alterations.基于基因改变的卵巢透明细胞癌精准医学
Int J Clin Oncol. 2020 Mar;25(3):419-424. doi: 10.1007/s10147-020-01622-z. Epub 2020 Feb 4.